Login to Your Account

Rolling NDA For Pseudobulbar Affect Ongoing

Avanir's Neurodex Now Ready For Neuropathic Pain Phase III

By Aaron Lorenzo

Friday, January 14, 2005
Avanir Pharmaceuticals Inc. received the FDA's blessing to begin a Phase III trial of Neurodex in pain, at the same time continuing work on its rolling new drug application in pseudobulbar affect. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription